TMOD1 and Alzheimer disease: While the assay had excellent NPV for Advanced (A+THIGH+) stage AD in the overall cohort and in the CI cohort (0.95 [0.92–1.0]), due to notable overlap between A+TMOD+ and A+THIGH+ plasma pTau217 levels, the PPV was poor (0.57 [0.44–0.69]).